Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Genomic Life to Present at Business Group on Health’s Annual Conference

Genomic Life

Genomic Life, a leading genome benefit management company with a mission of providing innovative benefit services to employers, will present at the Business Group on Health’s annual conference. The Business Group on Health’s annual conference brings together experts and employers related to health benefits and health care policies. This year’s theme is “Collaborating on the Future of Health and Well-Being,” and will be held between April 19-21, 2022 at the Renaissance Nashville Hotel. The company has an over-arching goal of making affordable clinical-grade genetic testing available to everyone, genetic testing plays an essential role in managing proactive health, informing individuals of their health risks and pre-existing conditions they would not have known about otherwise. Genomic Life helps facilitate the most appropriate testing at the highest quality labs with access to clear results and expert genetic counseling. These services help patients and their physicians turn those genetic insights into precise and timely actions. On Tuesday, April 19, 2022, from 9 – 11 a.m. CDT, Genomic Life will host an invite-only breakfast event panel at the nearby historic Union Station Nashville Hotel. Guests can also join virtually via Zoom. The panel will be focused on the future of proactive health and the power of genetic testing, hosted and moderated by WKRN-TV News anchor Nikki Burdine of “Good Morning Nashville,” and will feature Genomic Life executives, Karen Ferrell, MBA (Chief Executive Officer); Randy Scott, PhD (Executive Co-Chairman); Tod Klingler, PhD (Head of Product and Innovation); Robert Green, MD, MPH (Medical and Clinical Advisor); and Noël Rihm Obourn (Chief Commercial Officer). “Health technology is accelerating at a rapid pace and employers are looking for innovative ways to keep their employees healthy and engaged,” said Genomic Life CEO Karen Ferrell. “We are working with employers to take the guesswork out of genetic testing and services and help individuals and their own physicians be proactive and precise about their health and well-being.” On Wednesday, April 20, 2022 from 2-2:30 p.m. CDT, Genomic Life Executive Co-Chair Randy Scott, PhD will present a breakout session titled “Innovations in Cancer Screening and Genetic Testing” at the Business Group on Health’s annual conference. The discussion will cover how employers can leverage the power of genetic testing, precision medicine and clinical policy to strengthen their overall benefit strategy. Dr. Scott will be joined by Scott Osler, Vice President of Employer Partnerships at Grail, Inc. “Being in the field of genomics for more than 30 years, including leading the development of two revolutionary cancer diagnostic tests, I have learned a lot about how a preventive approach to healthcare can truly make a difference,” said Dr. Scott. “Our team at Genomic Life is hard at work offering comprehensive genetic testing services that span a lifetime of health benefits. We look forward to helping anyone and everyone we can make proactive, personalized and precise healthcare choices that positively impact their lives.” Genomic Life currently offers three types of genetic screenings to unlock precise and relevant healthcare insights, before illness occurs: Genetic Health Screen (GHS): A 147 gene panel that includes genetic predispositions to specific serious illnesses (cancers, cardiac, neurology, and more). Pharmacogenomics (PGx) Screen: With 25 biomarkers, this screen highlights drug-gene interactions and efficacy, informing the patient and physician which prescriptions and dosages are optimal, which are harmful, and which aren’t likely to do anything at all. Carrier Screen: A 289 gene panel that identifies critical recessive traits for those who are focused on family planning. The results include details about hereditary diseases that can be passed on to offspring and may compromise pediatric health. The results are coordinated with one’s OB-GYN to help take actions to understand and mitigate risks. Additionally, genomic insights are pivotal in the diagnosis and treatment of cancer; Genomic Life’s Cancer Guardian solution works with cancer patients and their own oncology team to facilitate best practices, ensuring that cancer patients benefit from the most precise, genomically-informed treatments. To learn more about Genomic Life and these events, please visit: https://info.genomiclife.com/lp/nbgh/. ### About Genomic Life Founded in 2017, Genomic Life is a leading genome benefit management company making affordable, clinical-grade genetic testing available to everyone, with a mission to provide innovative benefit services to employers. Genomic Life is helping close the gap in healthcare by working directly with employers to provide access to affordable genetic testing services that will enable them to seek better medical care and fill in the technology, innovation and healthcare gaps missed by health insurance companies.For more information, visit https://genomiclife.com. About Business Group on Health Business Group on Health is the leading non-profit organization representing large employers’ perspectives on optimizing workforce strategy through innovative health, benefits and well-being solutions and on health policy issues. The Business Group keeps its membership informed of leading-edge thinking and action on health care cost and delivery, financing, affordability and experience with the health care system. Business Group members include 72 Fortune 100 companies as well as large public-sector employers, who collectively provide health and well-being programs for more than 60 million individuals in 200 countries. For more information, visit www.businessgrouphealth.org. Contact Details The Hoyt Organization Cinnamon Thompson +1 310-373-0103 cthompson@hoytorg.com Company Website https://genomiclife.com/

April 19, 2022 09:00 AM Central Daylight Time

Image

TONGRENTANGCM (Hong Kong Stock Exchange: 03613) 2021 performance bucks the trend and rises Net profit reached HK$651 million, overseas business revenue increased by 30.6%

Beijing Tongrentang Chinese Medicine Co., Ltd.

HONG KONG SAR - Media OutReach - 19 April 2022 - Traditional Chinese medicine has played an important role in the prevention and control of the epidemic in recent years. In addition, the national policy has vigorously promoted the development of the industrial chain. Tongrentang, which has a brand history of more than 300 years, is actively seizing development opportunities. TONGRENTANGCM (03613), which is rooted in the Hong Kong market, revealed in its recently announced 2021 annual results announcement that its net profit reached HK$651 million, with its overseas market business revenue growing at a rapid rate of 30.6% against the trend. Both local and overseas business revenue in Hong Kong maintained high growth under the epidemic, demonstrating a stable business strategy and strong overseas development potential. The performance bucked the market and rose Strong internal and external operations The overall revenue of TONGRENTANGCM in 2021 was HK$1.556 billion, an increase of 18.3% over the same period last year, and its annual net profit reached HK$651 million, a year-on-year increase of 14.7%, of which the net profit attributable to shareholders of the listed company was HK$607 million, a year-on-year increase of 12.1%. The performance of the Hong Kong market maintained a steady growth rate, with a total revenue of HK$688 million, an increase of 26% over the previous year. The business in the overseas market achieved rapid growth, up 30.6% despite the raging global epidemic, fully demonstrating the capabilities of TONGRENTANGCM in the face of difficulties. It also reflects the potential of the Chinese medicine market overseas and in the future. Turning Crisis into Opportunity Innovating the TCM Services for International Markets Riding on the state's policies on traditional Chinese medicine business, TONGRENTANGCM seized the development opportunities, turned the crisis into an opportunity under the influence of the global epidemic, and actively explored the new ways in which traditional Chinese medicine can serve the world. Specialized in the prevention and control of the COVID19 epidemic, Tongrentang prescribed various TCM treatment programs and products for the prevention and control of the epidemic, successfully establishing a good brand reputation and image for overseas potential customers. In 2021, TONGRENTANGCM has won a number of international awards, including the 2021 Chinese Medicine Industrial Award issued by Chinese Medicine Industry Council of Australia Ltd., and the 2021 Most Influential Brand in Asia: Traditional Chinese Medicine Most Trustworthy Brand by Influential Brands, etc. Many international honors have certified the credibility and accreditation of Tongrentang's traditional Chinese medicine business overseas, which greatly enhances the confidence of foreign consumers in the brand. Fulfill social corporate responsibility Continue to contribute to epidemic prevention TONGRENTANGCM has always adhered to the corporate spirit of "Nurturing kindness and virtue, Preserving tranquility and wellness”", and have made various contributions to the society before and during the epidemic in Hong Kong. On March 2 this year, 100,000 boxes of Huoxiang Zhengqi Pian (lophanthus antifebrile tablet) worth nearly 6 million Hong Kong dollars were donated to the Hong Kong Special Administrative Region, and successively TONGRENTANGCM also donated a total value of nearly HK$700,000 of epidemic prevention and control materials, including COVID-19 Antigen Rapid Test kits, N95 anti-epidemic masks, Tongrentang traditional Chinese medicine, health drugs and food to various social welfare organizations, including Hong Kong's century-old charity organization Sik Sik Yuen, Self Help Group For the Brand Damaged, Neuro United, The Hong Kong Stroke Association, providing the social groups and the general public with the much needed anti-epidemic and health care assistance. Tongrentang donated 100,000 boxes of lophanthus antifebrile tablets worth nearly HK$6 million to the Hong Kong Special Administrative Region. Meanwhile, TONGRENTANGCM also took the initiative to offer purchase discounts on anti-epidemic products to many Chinese institutions and launched a special package of Ganoderma lucidum spore powder capsules to provide the public with more choices of anti-epidemic products. Currently, it is also planning to donate Antigen Rapid Test kits for COVID-19 to many nursing homes in Hong Kong, so that the elderly with limited mobility can also conduct self-testing, and further checking the epidemic situation in Hong Kong. Website︰ https://cm.tongrentang.com/ This press release is issued by Beijing Tongrentang Chinese Medicine Co., Ltd. Contact Details Beijing Tongrentang Chinese Medicine Co., Ltd. brandtrt@tongrentangcm.com

April 19, 2022 09:00 AM Eastern Daylight Time

Image

News Release

National Marrow Donor Program®/Be The Match® Implements Comcast Business Wavelength Services to Help Match Cancer Patients With Donors

Comcast Twin Cities

Comcast Business today announced that it is providing the National Marrow Donor Program® (NMDP)/Be The Match®, the leading global leader working to save lives through cellular therapy with a 10 Gbps optical wavelength service. The high-capacity, low-latency network solution will help Be The Match strengthen network performance, keeping its clients and employees connected, and in turn helping to ensure that transplant donors are connected to patients in need. Be The Match provides patients access to more than 39 million donors worldwide who step up to donate their marrow or blood stem cells. By connecting patients with donors and delivering life-saving cells to them, Be The Match provides cures to patients with life-threatening blood cancers and 75 blood diseases. The organization continues to lead the way in developing new cellular therapies, and in improving transplant accessibility and outcomes. Conducting this life-saving research while supporting and connecting patients to the resources they need requires a high-bandwidth, low-latency network connection. “Our network is becoming more critical, especially as we move to the cloud. If our systems aren’t available, people’s lives could be at stake,” said Robert Hanson, Vice President, Information Security, Infrastructure and Architecture, at Be The Match. “Comcast Business’ network performance has been seamless.” Comcast Business Wavelength Services deliver superior connectivity over a dense wave division multiplexing (DWDM) optical transport network with high levels of performance. Wavelength technology provides users with the ability to transport both Ethernet and non-Ethernet protocols. The point-to-point optical fiber network helps deliver data across several of Be The Match’s locations, including its headquarters in Minneapolis, its branch offices and its data center location. Since implementing Comcast Business’ services, Be The Match has been able to continue supporting patients across its various locations without concerns over network connectivity. Additionally, the reliable and fast network connections help position the organization for rising bandwidth demands and network growth, setting it up to serve its clients into the future. “To stay swift and competitive, businesses across industries continue to incorporate cloud and data center operations into their daily functions. With this will come the need for networking technology that can not only support the shifts in business today, but the continually rising bandwidth needs that the future demands,” said Wolfgang Lewis, Vice President for Comcast Business, Twin Cities Region. “Comcast Business is proud to support National Marrow Donor Program/Be The Match with its network services and do its part in making a difference in our communities.” About Comcast Business Comcast Business offers a suite of Connectivity, Communications, Networking, Cybersecurity, Wireless, and Managed Solutions to help organizations of different sizes prepare for what’s next. Powered by the nation’s largest Gig-speed broadband network, and backed by 24/7 customer support, Comcast Business is the nation’s largest cable provider to small and mid-size businesses and one of the leading service providers to the Enterprise market. Comcast Business has been consistently recognized by industry analysts and associations as a leader and innovator, and one of the fastest growing providers of Ethernet services. For more information, call 866-429-3085. Follow on Twitter @ComcastBusiness and on other social media networks at http://business.comcast.com/social. About National Marrow Donor Program®(NMDP)/Be The Match® The National Marrow Donor Program®(NMDP)/Be The Match® is the leading global partner working to save lives through cellular therapy. With more than 30 years of experience managing the most diverse registry of potential unrelated blood stem cell donors and cord blood units in the world, NMDP/Be The Match is a proven partner in providing cures to patients with life-threatening blood and marrow cancers and diseases. Through their global network, they connect centers and patients to their best cell therapy option—from blood stem cell transplant to a next-generation therapy—and collaborate with cell and gene therapy companies to support therapy development and delivery through Be The Match BioTherapies®. NMDP/Be The Match is a tireless advocate for the cell therapy community, working with hematologists/oncologists to remove barriers to consultation and treatment, and supporting patients through no-cost programs to eliminate non-medical obstacles to cell therapy. In addition, they are a global leader in research through the CIBMTR®(Center for International Blood and Marrow Transplant Research®)—a collaboration with Medical College of Wisconsin, investing in and managing research studies that improve patient outcomes and advance the future of care. Contact Details Comcast Jill Hornbacher Jill_Hornbacher@comcast.com Finn Partners Chloe Huard chloe.huard@finnpartners.com Company Website https://twincities.comcast.com/

April 19, 2022 08:00 AM Eastern Daylight Time

G Medical Innovations Holdings Ltd Announces $7.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

G Medical Innovations Holdings

TEL AVIV and NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- G Medical Innovations Holdings Ltd. (NASDAQ:GMVD) (the "Company"), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor to purchase 5,000,000 ordinary shares (or ordinary shares equivalents) in a private placement priced at-the-market under Nasdaq rules. The Company will also issue to the investor warrants to purchase up to an aggregate of 6,250,000 ordinary shares. The purchase price for one ordinary share and one warrant to purchase one ordinary share is $1.50. The warrants have an exercise price of $1.50 per ordinary share, will be immediately exercisable, and will expire five years from issuance. A.G.P./Alliance Global Partners is acting as the sole placement agent for offering. The gross proceeds from the private placement are expected to be $7.5 million before deducting placement agent fees and other offering expenses. The Company intends to use the net proceeds from the offering for the repayment of existing debt and working capital purposes. The private placement is expected to close on or about April 20, 2022, subject to the satisfaction of customary closing conditions. The Company also has agreed that certain warrants to purchase an aggregate of 2,400,000 ordinary shares of the Company that were issued to the investor in February 2022 will be amended to have a reduced exercise price of $1.50 per ordinary share. The offer and sale of the foregoing securities are being made in a transaction not involving a public offering and the securities have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. Under an agreement with the investors, the Company agreed to file a registration statement with the Securities and Exchange Commission (the "SEC") covering the resale of the ordinary shares to be issued to the investors (including the ordinary shares issuable upon the exercise of the warrants) no later than 30 days after the closing and to use commercially reasonable efforts to have the registration statement declared effective as promptly as practical thereafter, and in any event no later than 60 days in the event of a "full review" by the SEC. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial stage healthcare company engaged in the development of next generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical grade device that can transform almost any smartphone into a medical monitoring device enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses the closing of the private placement and the expected use of proceeds. Because such statements deal with future events and are based on G Medical’s current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical could differ materially from those described in or implied by the statements in this press release. The forward looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details G Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Kobi@gmedinnovations.com Company Website https://gmedinnovations.com/

April 18, 2022 07:00 AM Eastern Daylight Time

AmeriLife’s Senior Market Advisors Partners With Buffalo Health Advisors

AmeriLife

Senior Market Advisors (SMA), one of the fastest growing field marketing organizations (FMO) in the insurance space and an affiliate of AmeriLife Group, LLC (“AmeriLife”), announced today that it has partnered with Buffalo Health Advisors, one of the top health insurance distributors in Tennessee that specializes in Medicare Advantage, Medicare Supplement and PDP solutions, as well as health insurance for the under-65 market. The partnership brings more than 450 field agents in Buffalo’s network under the SMA banner, while also expanding SMA’s geographical footprint in the southeast United States. Per the agreement, terms of the deal were not disclosed. “Buffalo Health Advisors is a dynamic and exciting force in our industry,” said Andy Watkins, vice president of sales and agency development, East region, for Senior Market Advisors. “Senior Market Advisors and AmeriLife are excited to start leveraging our multiple synergies to promote its overall growth and the betterment of our Medicare beneficiaries.” “Simply, Buffalo Health Advisors has always been about bringing the very best marketing strategies, business services and fun to our agent partners,” added Joshua Borders, owner and vice president of sales for Buffalo Health Advisors. “We’re very excited to partner with SMA and AmeriLife to unlock amazing new tools, technologies and relationships for our partners and clients. We’ve only just begun!” While Buffalo Health Advisors will continue to operate as a stand-alone organization in SMA’s downline, it will consolidate its office resources at SMA’s Nashville, Tennessee, headquarters. Likewise, Borders will continue to oversee Buffalo’s day-to-day operations, reporting to SMA’s Vice President of Corporate Operations Victoria Buckman. ### About AmeriLife AmeriLife’s strength is its mission: to offer insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a national distribution network of over 300,000 insurance agents and advisors, more than 50 marketing organizations, and 50 insurance agency locations. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. About Senior Market Advisors Senior Market Advisors (SMA) has been people over profits since 2007, by hard work and a commitment to “doing right” by the consumer. We have certainly knocked on our fair share of doors. We know the grit and determination involved in becoming a career agent. And as a result, we have become one of the fastest growing FMOs, doubling our business each year for the past five years. For more information, visit us online at SeniorMarketAdvisors.com. Contact Details AmeriLife Communications Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Senior Market Advisors Communications Sarah Smith ssmith@seniormarketadvisors.com AmeriLife Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

April 14, 2022 02:00 PM Eastern Daylight Time

Industrial Defender Unveils New Standalone OT Vulnerability Management Solution, Immunity by ID™

Industrial Defender

Industrial Defender, the leader in operational technology (OT) security, today announced the launch of Immunity by ID™, a new cloud-based offering that helps industrial security teams turn their OT asset inventory information into a risk-based vulnerability management program. The product is offered as a standalone solution or as an add-on within the Industrial Defender platform. Using current OT hardware and software inventory information from an asset visibility tool, CMDB or spreadsheet, this vendor-agnostic solution generates a prioritized list of vulnerabilities based on asset criticality and risk level, along with applicable patching data, to help keep critical infrastructure secure in the face of global cybersecurity threats. Immunity by ID is up and running in a matter of days, allowing users to begin their vulnerability management program immediately, and simple, transparent pricing lets them easily scale a subscription as they mature. “With the looming threat of a global cyber war, critical infrastructure organizations of all sizes are looking for straightforward solutions that rapidly deliver actionable intelligence to help them protect their essential systems,” said Peter Lund, CTO at Industrial Defender. “We created this tool to help companies better utilize the asset information they already have that may be nothing more than a data dump right now. Unlike other OT vulnerability management offerings on the market, ours is powered by an anonymized cloud, so as soon as a vulnerability is published, you'll know whether a device is at risk without waiting for the next software update.” Industrial Defender will be offering a free 14-day trial of Immunity by ID to qualified users at North American and European critical infrastructure companies through the end of May to support their efforts to shore up cybersecurity defenses. For more information, visit https://www.industrialdefender.com/immunity-by-industrial-defender/. About Industrial Defender Since 2006, Industrial Defender has been solving the challenge of safely collecting, monitoring, and managing OT asset data at scale, while providing cross-functional teams with a unified view of security. Their specialized solution is tailored to complex industrial control system environments by engineers with decades of hands-on OT experience. Easy integrations into the broader security and enterprise ecosystem empower IT teams with the same visibility, access, and situational awareness that they’re accustomed to on corporate networks. Learn more at www.industrialdefender.com. Contact Details Erin Anderson +1 617-675-4206 eanderson@industrialdefender.com Company Website https://www.industrialdefender.com

April 14, 2022 09:00 AM Eastern Daylight Time

PathPresenter Introduces ClinPx™ - A Clinical Enterprise Platform

PathPresenter

Pilot installation at The Ohio State University integrates ClinPx into Epic’s Beaker Laboratory Information System (LIS), allowing The Ohio State University (OSU) pathologists to receive, view, and sign out cases – uploaded from around the world – directly in Beaker. PathPresenter, the premier digital pathology platform for education and conferences with more than 40,000 users and 20+ institutional licenses, now presents to clinical users a best-in-class clinical enterprise platform, ClinPx. ClinPx is a custom, institution-branded, clinical enterprise platform that enables pathology consultations to be directly viewed and reported in your institution’s LIS through our proprietary backend HL7 messaging engine. It has inbuilt quality control (QC) ensuring whole slide images are of diagnostic quality and has the ability to integrate validated AI models into the scanner-agonistic viewer. ClinPx allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists as well as bidirectional communication channels for ordering stains and recuts. It also enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. This functionality brings the control and organization of the clinical workflow back to the end user. Our first pilot installation with The Ohio State University Wexner Medical Center and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) integrates ClinPx into Epic’s Beaker LIS, allowing pathologists at The Ohio State University to receive, view, and sign out cases uploaded from around the world directly in Beaker. “Our goal is to use ClinPix to augment OSU’s pathology clinical consultation capabilities globally. ClinPx has the ability to integrate with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate,” said Dr. Anil Parwani, vice chair of anatomic pathology at The Ohio State University College of Medicine. Rajendra Singh, co-founder of PathPresenter, added “ClinPX creates a solution to allow for the integration of digital pathology into existing workflows used by pathologists without disruption.” This platform is installed as a pilot project at The Ohio State University for potential expansion of its digital pathology consultation service. Dr. Parwani has no personal conflicts of interest to disclose. About PathPresenter PathPresenter is the world’s most widely used digital pathology platform, with a community of more than 40,000 users in 172 countries and 20+ institutional licenses. Our educational and conference module provides a seamless environment for pathologists, radiologists, clinicians, and life science researchers to use, share and collaborate with fellow clinicians throughout the world to learn, teach, present, perform research, and practice better medicine, while connecting industry to a global community of clinicians and researchers. Get started with PathPresenter, for free, at https://pathpresenter.net/. Our new ClinPX TM clinical enterprise platform helps hospitals and labs expand the reach of their clinical consultation (2 nd opinion) services globally, increase their efficiency, and optimize the user experience for both consulting pathologists and client pathologists. Through deep integration with the institution’s existing laboratory information system (LIS), consulting pathologists can receive, view, and sign out cases uploaded from around the world directly in the LIS. ClinPX allows a seamless and intuitive consultation workflow, as well as in-house consensus, tumor board meetings or live discussions with referring pathologists in addition to bidirectional communication channels for ordering stains and recuts. Further, it enables routing interesting cases into folders for de-identification and use in tumor boards, conferences, research, or education. Through a robust API, ClinPX integrates with multiple AI vendors with the overall goal of improving patient care and making pathology diagnosis more robust, timely and accurate. Contact Details PathPresenter Cory Batenchuk - SVP of Operations +1 873-355-9913 cory@pathpresenter.com Company Website https://pathpresenter.net

April 13, 2022 11:00 AM Eastern Daylight Time

Metabolic fitness platform Ultrahuman acquires consumer-focused wearable company LazyCo

Ultrahuman

Ultrahuman, the world’s most advanced metabolic fitness platform, has today announced the acquisition of consumer-focused wearable company LazyCo famed for creating the Aina ring wearable. LazyCo will integrate with Ultrahuman’s global in-house hardware development team as they seek opportunities to enhance the user experience and help improve global metabolic health standards. Ultrahuman will leverage the LazyCo team’s expertise to generate deeper metabolic insights and better overall health insights for consumers. The metabolic health crisis is unarguably one of the largest healthcare crises that exist today. Over a billion people in the world suffer from a metabolic health disorder which contributes to almost 85% of all chronic diseases in the world. By helping people understand how food and exercise affect their metabolic health, people would be able to make informed choices about what they eat and their activity levels. The approach is a geography/diet agnostic way to help people eat and exercise better. Measuring a powerful biomarker like glucose can reveal so much about how a particular food item affects the user’s metabolic health by measuring the glucose response. This response is unique to an individual and it depends on various factors like their gut microbiome diversity, stress levels, time of the day, food ingredient quality, etc. With this acquisition, the idea would be to expand the set of real-time biomarkers that could provide unique health insights upon correlation. LazyCo was founded by engineers turned product designers, Apoorv Shankar and Yogansh Namdeo in 2017. The company focused on building hardware products that made daily life easier. One of the notable products included the Aina Ring - an AI-powered smart ring designed to predict and automate daily tasks without the need to take the phone out of the pocket. Digital tasks such as booking cabs, controlling smart home devices, activating SOS alerts, and taking phone calls, were 7x faster and easier through the ring. LazyCo completed a successful Kickstarter campaign in 2019 and won several design and startup awards from the likes of Alibaba and Qualcomm. “Ultrahuman’s vision of making health more personalized and impactful for people syncs with LazyCo’s vision of building products that solve problems for people in the most effortless ways. Together, we can create a deeper impact on the overall health of the world,” said Apoorv Shankar, Co-Founder and CEO, LazyCo. Ultrahuman launched with a wearable (the “Ultrahuman M1”) - a metabolic health tracking platform that provides intelligent nudges based on glucose biomarkers. This helps people optimize their exercise, sleep and nutrition based on deep insights from the platform. The M1 tracks the wearer’s metabolism as they go about their day. It triggers timely nudges to the user such as alerts to a high blood glucose event and suggestions to take a walk for optimizing their glucose levels. “We want to make it easy to get healthy. At Ultrahuman, we’re deep believers in passive personalized health, specifically in a health platform that requires very minimal effort from a user’s perspective. This perfectly aligns with the philosophy of LazyCo.” said Mohit Kumar, Founder and CEO, Ultrahuman. Ultrahuman was started by Mohit Kumar and Vatsal Singhal who were also co-founders at Runnr which later merged with India’s largest food delivery service Zomato. Mohit is an avid cyclist, biohacker and Brazilian Jiu-Jitsu enthusiast. Vatsal is a cross-fit enthusiast and a biohacker. Mohit was training at one of the largest MMA Camps in the world (Tiger Muay Thai in Thailand). There, he observed athletes train smartly via the usage of data, recovery tools and protocols. He got together with Vatsal and they came up with a vision for Ultrahuman where they can make the journey of fitness for people more personalized and impactful. Ultrahuman is a venture-backed startup that has raised $25m to date. Their investors include Alpha Wave Incubation (AWI), which is backed by DisruptAD and managed by Falcon Edge, Steadview Capital, Nexus Venture Partners, Blume Ventures and Utsav Somani’s iSeed fund, and a range of marquee founders and angel investors including Tiger Global’s Scott Schleifer. About Ultrahuman Ultrahuman is the world's most advanced metabolic fitness platform. By using glucose and other biomarkers, Ultrahuman is helping people improve their energy levels, lose fat and avoid metabolic disorders. For more information and updates on Ultrahuman, please visit ultrahuman.com or follow us on Facebook, Instagram, Twitter, LinkedIn, and YouTube. Contact Details Ultrahuman Bilal Mahmood +44 7714 007257 b.mahmood@stockwoodstrategy.com Company Website https://ultrahuman.com/

April 12, 2022 09:00 AM Eastern Daylight Time

Image

Q-VANT Biosciences enters Vaccine Research Master Agreement with Kansas State University

Q-Vant Biosciences

Q-VANT Biosciences, the first company to achieve a 100% sustainable way to meet the growing global vaccine market demand for Quillaja saponin-based adjuvants, today announced that it has signed a Master Agreement with Kansas State University’s College of Veterinary Medicine to test and evaluate its saponin-based adjuvants in several of the university’s veterinary vaccines. Among the most highly regarded universities in the nation for veterinary vaccine science, K-State is home to the Biosecurity Research Institute, a world-renowned high-security containment facility. The Master Agreement will benefit Q-VANT and the university. The first project under the agreement will compare Q-VANT’s 100% sustainable saponin-based adjuvants to other known adjuvants utilizing K-State’s subunit classic swine fever (CSF) vaccine. This study will further the university’s instructional and research project objectives while advancing its vaccine development program. For Q-VANT, the study will serve to validate the safety and efficacy of the company’s Quillaja saponin-based adjuvants. “We’re excited to be working with Kansas State University and are looking forward to demonstrating the safety and efficacy of our adjuvants for widespread use in the global veterinary pharmaceutical market. The CSF field trial is the first of many we hope to perform with K-State using our 100% sustainable saponin-based adjuvants,” said Q-VANT’s Chief Commercial Officer, Juan Jose Allbarran. The CSF vaccine was developed by K-State professor Dr. Jishu Shi. Dr. Shi also serves as the director of the U.S.-China/Asia Center for Animal Health, where he and his team are working on novel vaccine and diagnostic strategies that are aimed at better control and prevention measures targeting swine infectious diseases. This includes porcine reproductive and respiratory syndrome (PRRS), classical swine fever virus (CSF), African swine fever (ASF) and other emerging viral diseases of swine. “This partnership is an exciting opportunity for all involved,” said Dr. Shi. “Our students will have the opportunity to take part in a research project that has the potential to have a major positive impact globally in animal vaccine development and usage.” About Q-VANT Biosciences Q-VANT is a privately held biosciences company that has solved the supply chain problem of QS-21 and other Quillaja-based saponin adjuvants for the global human and animal pharmaceutical markets. The company's next-generation technology platform combines computational learning techniques with a proprietary multi-step purification process to increase the supply of QS-21 by more than 1,000 times - enabling the production of billions of doses annually to meet today's increasing global market demand. Led by a team with unrivaled experience in vaccine and adjuvant development, manufacturing and global regulatory requirements, and with world-class knowledge in Quillaja saponin supply chain, agronomy, extraction and purification, Q-VANT is the first company that is vertically integrated to combine a secured sustainable Quillaja raw material supply with pharma cGMP commercial-scale production of QS-21 and other saponin-based adjuvants. For more information, visit www.q-vant.com. Contact Details Hillary Lima +1 401-490-9700 q-vant@svmpr.com Company Website https://q-vant.com/

April 12, 2022 08:00 AM Eastern Daylight Time

1 ... 231 232 233 234 235 ... 310

Back